Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Schering's Claritin-D

This article was originally published in The Tan Sheet

Executive Summary

Schering's Claritin-D: FDA approves a 24-hour extended-release tablet formulation Aug. 23. The company plans to launch the once-daily Rx antihistamine/decongestant combo (10 mg loratadine, 240 mg pseudoephedrine) in early September at an average wholesale price of $2.28 per day, equivalent to the price of a day's therapy with twice-daily Claritin-D. Claritin (loratadine) has been available since April 1993 and is the top-selling antihistamine in the U.S. It continues to show strong growth, with a gain of 38% to $347 mil. for the second quarter. Claritin-D 12-hour extended-release (5 mg loratadine, 120 mg pseudoephedrine) was approved in November 1994...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel